These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 24979133)
1. Chrysin, apigenin and acacetin inhibit tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) on activated RAW264.7 macrophages. Warat M; Szliszka E; Korzonek-Szlacheta I; Król W; Czuba ZP Int J Mol Sci; 2014 Jun; 15(7):11510-22. PubMed ID: 24979133 [TBL] [Abstract][Full Text] [Related]
2. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925 [TBL] [Abstract][Full Text] [Related]
3. The role of selected flavonols in tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) expression on activated RAW 264.7 macrophages. Warat M; Sadowski T; Szliszka E; Król W; Czuba ZP Molecules; 2015 Jan; 20(1):900-12. PubMed ID: 25580686 [TBL] [Abstract][Full Text] [Related]
4. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. Oishi M; Iizumi Y; Taniguchi T; Goi W; Miki T; Sakai T PLoS One; 2013; 8(2):e55922. PubMed ID: 23431365 [TBL] [Abstract][Full Text] [Related]
5. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930 [TBL] [Abstract][Full Text] [Related]
7. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723 [TBL] [Abstract][Full Text] [Related]
8. The natural flavones, acacetin and apigenin, induce Cdk-Cyclin mediated G2/M phase arrest and trigger ROS-mediated apoptosis in glioblastoma cells. Shendge AK; Chaudhuri D; Mandal N Mol Biol Rep; 2021 Jan; 48(1):539-549. PubMed ID: 33394232 [TBL] [Abstract][Full Text] [Related]
9. Apigenin promotes TRAIL-mediated apoptosis regardless of ROS generation. Kang CH; Molagoda IMN; Choi YH; Park C; Moon DO; Kim GY Food Chem Toxicol; 2018 Jan; 111():623-630. PubMed ID: 29247770 [TBL] [Abstract][Full Text] [Related]
10. Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment. Liguori M; Buracchi C; Pasqualini F; Bergomas F; Pesce S; Sironi M; Grizzi F; Mantovani A; Belgiovine C; Allavena P Oncotarget; 2016 Jul; 7(27):41662-41676. PubMed ID: 27191500 [TBL] [Abstract][Full Text] [Related]
11. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Horinaka M; Yoshida T; Shiraishi T; Nakata S; Wakada M; Sakai T Mol Cancer Ther; 2006 Apr; 5(4):945-51. PubMed ID: 16648565 [TBL] [Abstract][Full Text] [Related]
12. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Hougee S; Sanders A; Faber J; Graus YM; van den Berg WB; Garssen J; Smit HF; Hoijer MA Biochem Pharmacol; 2005 Jan; 69(2):241-8. PubMed ID: 15627476 [TBL] [Abstract][Full Text] [Related]
17. Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. McManus S; Chamoux E; Bisson M; Roux S Apoptosis; 2012 Feb; 17(2):121-31. PubMed ID: 21972115 [TBL] [Abstract][Full Text] [Related]
19. TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. Mohr A; Yu R; Zwacka RM BMC Cancer; 2015 Jul; 15():494. PubMed ID: 26138346 [TBL] [Abstract][Full Text] [Related]
20. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]